An international consortium of scientists set out to test the effectiveness of a candidate vaccine known as rVSV-ZEBOV in an open-label, cluster-randomized trial involving over 9,000 participants during the Ebola outbreak in West Africa in 2015. The recombinant, replication-competent, vesicular stomatitis virus-based vaccine expressing the glycoprotein of a Zaire Ebolavirus (rVSV-ZEBOV), is protective in challenge models in several animal species, including mice, hamsters, guinea pigs, and non-human primates.
A single dose completely protected non-human primates against high-dose challenge (around 1000 particle-forming units) when administered between 7 and 31-day pre-challenge and partly protected non-human primates when administered from 3 days before 7 to 24 h after challenge with the Makona strain responsible for the west African epidemic. The rVSV-ZEBOV vaccine has been studied in…
